Table 2 Patient diagnoses, relapse status, and treatment status over time
From: Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
Clinical and laboratory data | Baseline | 1 year | 2 years | 4 years |
|---|---|---|---|---|
Number of subjects | 41 | 41 | 40 | 39 |
Diagnosis (CIS/RRMS) | 19/22 | 12/29 | 9/31 | 7/32 |
Relapse within last 2 months (yes/no) | 23/18 | 4/37 | 2/38 | 2/37 |
Treatment (number of subjects) | ||||
No DMT | 41 | 17 | 18 | 18 |
Interferon-β 1b | 0 | 18 | 12 | 5 |
Interferon-β 1a | 0 | 1 | 1 | 1 |
Dimetylfumarate | 0 | 0 | 0 | 2 |
Fingolimod | 0 | 1 | 2 | 3 |
Natalizumab | 0 | 4 | 7 | 10 |